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Abstract
Background Novel tuberculosis (TB) drugs and the need
to treat drug-resistant tuberculosis (DR-TB) are likely to
bring about substantial transformations in TB treatment in
coming years. An evidence base for cost and cost-effec-
tiveness analyses of these developments is needed.
Objective Our objective was to perform a review of pa-
pers assessing provider-incurred as well as patient-incurred
costs of treating both drug-susceptible (DS) and multidrug-
resistant (MDR)-TB.
Methods Five databases (EMBASE, Medline, the Na-
tional Health Service Economic Evaluation Database, the
Cost-Effectiveness Analysis Registry, and Latin American
and Caribbean Health Services Literature) were searched
for cost and economic evaluation full-text papers contain-
ing primary DS-TB and MDR-TB treatment cost data
published in peer-reviewed journals between January 1990
and February 2015. No language restrictions were set. The
search terms were a combination of ‘tuberculosis’, ‘mul-
tidrug-resistant tuberculosis’, ‘cost’, and ‘treatment’. In the
selected papers, study methods and characteristics, quality
indicators and costs were extracted into summary tables
according to pre-defined criteria. Results were analysed
according to country income groups and for provider costs,
patient costs and productivity losses. All values were
converted to $US, year 2014 values, so that studies could
be compared.
Results We selected 71 treatment cost papers on DS-
TB only, ten papers on MDR-TB only and nine papers
that included both DS-TB and MDR-TB. These papers
provided evidence on the costs of treating DS-TB and
MDR-TB in 50 and 16 countries, respectively. In 31 %
of the papers, only provider costs were included; 26 %
included only patient-incurred costs, and the remaining
43 % estimated costs incurred by both. From the pro-
vider perspective, mean DS-TB treatment costs per pa-
tient were US$14,659 in high-income countries (HICs),
US$840 in upper middle-income countries (UMICs),
US$273 in lower middle-income (LMICs), and US$258
in low-income countries (LICs), showing a strong posi-
tive correlation. The respective costs for treating MDR-
TB were US$83,365, US$5284, US$6313 and US$1218.
Costs incurred by patients when seeking treatment for
DS-TB accounted for an additional 3 % of the provider
costs in HICs. A greater burden was seen in the other
income groups, increasing the costs of DS-TB treatment
by 72 % in UMICs, 60 % in LICs and 31 % in LMICs.
When provider costs, patient costs and productivity
losses were combined, productivity losses accounted for
16 % in HICs, 29 % in UMICs, 40 % in LMICs and
38 % in LICs.
Conclusion Cost data for MDR-TB treatment are limited,
and the variation in delivery mechanisms, as well as the
rapidly evolving diagnosis and treatment regimens, means
that it is essential to increase the number of studies
assessing the cost from both provider and patient per-
spectives. There is substantial evidence available on the
costs of DS-TB treatment from all regions of the world.
The patient-incurred costs illustrate that the financial
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burden of illness is relatively greater for patients in poorer
countries without universal healthcare coverage.
Key Points for Decision Makers
Drug-susceptible tuberculosis treatment cost data are
available from the perspective of both providers and
patients from various settings around the world.
Multidrug-resistant tuberculosis treatment costs are
not widely available, particularly not for middle- and
low-income countries.
Productivity losses were presented in 57 % of the
papers, for both drug-susceptible and multidrug-
resistant tuberculosis. However, methods used varied
widely, reflecting the lack of clear guidelines on the
best instrument and methods for this estimation.
1 Introduction
The post-2015 World Health Organisation (WHO) End TB
strategy 2016–2035 has a vision of a ‘world free of tu-
berculosis (TB) (zero deaths, disease or suffering due to
TB)’ and a goal of ‘ending the global TB epidemic’ by
2035, defined as an annual incidence of fewer than ten
cases per 100,000 of population [1]. These targets are
likely to require scaling-up of high-quality drug-sensitive
(DS) TB and drug-resistant (DR) TB treatment, but may
stretch the resource capacity of national TB programmes
far beyond any previous efforts. Country- and context-
specific economic evaluations and budget impact analyses
are essential for decision making, but obtaining timely cost
data can be expensive and labour intensive. Assembling a
repository of quality-assessed DS-TB and multidrug-re-
sistant (MDR)-TB treatment costs can facilitate these
processes and identify gaps for future targeted cost data
collection.
Earlier reviews have investigated TB treatment costs, but
these are either incomplete or no longer up to date. We
identified eight previous reviews on TB treatment costs. In
1997, Fryatt [2] reviewed cost-effectiveness papers of TB
treatment programmes, in 2004, Russell [3] reviewed the
economic burden of households due to TB, and, in 2011,
Verdier et al. [4] reviewed economic evaluations of TB
control in high-income countries (HICs). Three reviews
were published in 2012: two on patient-incurred TB treat-
ment costs in sub-Saharan Africa [5, 6] and one on MDR-
TB treatment costs [7]. In 2013, Diel et al. [8] published a
review determining the costs of TB in the EU, and, in 2014,
Tanimura et al. [9] reviewed papers on patient costs in low-
and middle-income countries [9]. This present review
complements and synthesises the evidence provided in these
previous reviews by including papers from all countries,
assessing both DS-TB and MDR-TB costs, and evaluating
both provider- and patient-incurred costs.
2 Methods
2.1 Search Strategy and Data Extraction
Peer-reviewed papers were eligible for inclusion if mean
treatment cost estimates of DS-TB or MDR-TB in adults
were reported and based on primary data that originated
from 1990 or later. Five databases were searched:
EMBASE, Medline, the National Health Service Economic
Evaluation Database, the Cost-Effectiveness Analysis
Registry, and the Latin American and Caribbean Health
Sciences Literature. An initial search was conducted in
April 2013 and updated in February 2015. Therefore, the
search period was from January 1990 to February 2015.
Search terms were a combination of ‘tuberculosis’, ‘mul-
tidrug-resistant tuberculosis’, ‘cost’, and ‘treatment’. The
full search strategies are included in the Electronic Sup-
plementary Material (ESM) Online Resource 1. No lan-
guage restrictions were applied in the search. To assess
relevance, abstracts or papers in Spanish were translated by
the authors, and abstracts obtained in French, Hungarian
and Russian were translated using electronic translation
software (Google Translate) [10]. Reference lists of iden-
tified reviews were checked for papers that may have been
missed by the database search; references cited in retrieved
papers were also examined.
Data were independently extracted by two authors. Any
discrepancies were resolved by re-evaluation of the paper
in question. A data extraction sheet was used, the compo-
sition of which was informed by the data-extraction
guidelines for economic evaluations in the Centre for Re-
views and Dissemination’s Guidance for Undertaking Re-
views in Health Care [11] and the Cochrane Handbook for
Systematic Reviews of Interventions [12]. Variables in-
cluded the characteristics of the study, as well as provider-
and patient-incurred costs. The outcome measure was mean
treatment costs per patient. For each paper, all cost items
reported, such as drugs, hospitalisation, diagnostic tests and
productivity loss, were extracted separately and, where
relevant, divided into patient-incurred and provider costs.
Patient-incurred costs were further divided into direct costs
and productivity losses. Direct patient costs were defined as
expenses paid by patients for receiving treatment, such as
user fees for health facilities or monitoring or diagnostic
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tests, drug expenditures, transportation and other costs,
which included food, non-TB drugs, traditional medicine
and room and board for patients not resident near the TB
treatment facility. Moreover, if costs were aggregated, this
total was included in the ‘other’ category. Productivity
losses were defined as the value of paid and unpaid pro-
duction loss due to time seeking treatment, being ill, or
because of premature mortality [13].
Given that our aim was to provide a dataset that best
informs the estimation of current TB treatment costs, in
papers that compared the costs of more than one treatment
delivery strategy, for instance directly observed treatment
(DOT) versus self-administered treatment (SAT) [14], we
selected the intervention we considered to best reflect the
current standard practice in the respective country. This was
determined from the paper, or, if not stated, by consulting
with TB experts familiar with the respective countries.
2.2 Data Analysis
Costs were converted to 2014 values in the local currency
and then to US$ using the International Monetary Fund’s
average consumer price indices and OANDA’s average
annual exchange rates [15, 16]. For papers that did not
provide the year of cost data, we used the year prior to the
publication date.
Results were presented according to 2013 World Bank
country income groups. HICs were classified as those with
per capita gross national income (GNI) of US$12,746 or
greater, upper middle-income countries (UMICs) greater
than or equal to US$4126 and less than US$12,746, lower
middle-income countries (LMICs) greater than or equal to
US$1046 and less than US$4126, and low-income coun-
tries (LICs) less than US$1046 [17].
The relationship between provider costs and country
GNI per capita was assessed using Pearson’s correlation
coefficient.
2.3 Study Quality Assessment
Quality assessment focused on methods for estimating and
reporting costs; methods used for determining health effects
as part of cost-effectiveness studies were not evaluated.
Quality appraisal was based on two guidelines; the Con-
solidated Health Economic Evaluation Reporting Standards
(CHEERS) statement [18] and The Tool to Estimate Pa-
tient’s Costs published by the TB Coalition for Technical
Assistance (TBCTA) [19]. Four requirements of the
CHEERS statement were used: (1) sources used for resource
quantities and unit costs clearly described, (2) dates of es-
timated resource quantities and unit costs reported, (3)
methods for adjusting unit costs to the reporting year and
performing currency conversion explained, and (4) mean
values for main categories of estimated costs reported [18].
For papers that included patient costs, quality was further
evaluated using two requirements of the TBCTA tool: (1)
clear description of patient interview procedures given and
(2) methods used for valuing productivity losses explained
and justified [19]. Additional quality indicators abstracted
from all papers were the number of patients included in the
study sample in order to provide some indications of rep-
resentativeness [20, 21]. We also extracted whether any
measures of dispersion, such as standard deviation (SD),
around the mean cost values were given [22]. The review
protocol was not registered in any systematic review data-
base or registry. Two authors independently assessed paper
quality, with disagreements resolved through discussion.
3 Results
3.1 Paper Selection
The search identified 4899 papers, and 289 papers were
included for full-text review, after which 199 papers were
excluded (Fig. 1). Of the excluded papers, 42 presented
costs of TB screening in schools or in high-risk individuals,
such as immigrants, healthcare workers, individuals with
HIV or the elderly. Reporting was insufficient in 28 papers,
including only presenting selected cost items or providing
costs of a national TB programme without mean treatment
costs per patient; 11 papers were excluded because the
same primary data were used in an already included paper.
A total of 90 papers were included in the analysis; 71 were
on DS-TB treatment costs only, nine were on MDR-TB
only, and ten included the costs of both.
3.2 Study Characteristics
For DS-TB and MDR-TB, 50 and 16 countries were rep-
resented, respectively (Table 1). In this review we distin-
guished between paper and study to illustrate where a paper
included cost values for two or more countries, which
would thereby represent two or more studies in one paper.
Therefore, a total of 95 studies were represented in this
review. The oldest paper was from 1995; six papers were
from 2014 and one was from 2015, as of the February 2015
search. Country income groups were relatively evenly
represented; 28 % of the papers were from HICs, 32 %
from UMICs, 19 % from LMICs, and 21 % from LICs.
In 51 papers, only one type of TB treatment manage-
ment was evaluated (for example, ambulatory DOT), while
the remaining 39 papers compared two or more strategies
in either a cost-comparison or a cost-effectiveness analysis.
In 31 % of the papers, only provider costs were in-
cluded, in 26 % only costs incurred by patients, and in the
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remaining 43 % both provider and patient costs were
evaluated (Table 1). This varied according to country in-
come group. While a provider-only perspective was taken
in 15 and 11 of the HIC and UMIC papers (60 and 38 %,
respectively), only one LMIC paper (6 %) and one LIC
paper (5 %) included provider costs only. Productivity
losses were included in 81 % of the papers that measured
patient-incurred costs.
3.3 Quality Assessment
Quality assessment of individual papers is included in the
ESM (Online Resources 2 and 3). Table 2 presents a
summary according to country income group.
3.3.1 Data Collection Methods
The year of cost data and the main cost categories were
adequately reported in 77 % of papers (Table 2). In 79 of
the 90 papers, cost data were collected from a sample of
patients. The mean sample size across these studies were
324 patients (SD 532), ranging from nine in a MDR-TB
study from the UK to 3510 patients in a German cost-of-
illness study [23, 24]. However, in spite of relatively large
sample sizes in many studies, only 30 % presented de-
scriptive statistics showing the spread around the mean cost
values.
In ten of the remaining 11 studies, costs were determined
by making assumptions about resources needed to treat TB
according to national guidelines. For instance, a South
African study by Pooran et al. [25] assumed that all DS-TB
patients received drugs for 6 months and MDR-TB patients
for 24 months, as this was the length of a full recommended
treatment course. In the one study [26] that did not follow
this approach, annual costs of primary health clinics in a
specific area of South Africa were estimated and costs of TB
treatment were determined by weighing total costs by the
proportion of patients presenting due to TB [26].
Records idenﬁed through 
database searching  
(n = 5332)
Addional records idenﬁed 
through other sources  
(n = 195)
Records aer duplicates removed  
(n = 4899) 
Records screened  
(n = 4899) 
Records excluded  
(n = 4610) 
Full-text papers assessed 
for eligibility  
(n = 289)
Full-text papers excluded  
(n = 199) 
No primary data (n = 62) 
TB screening only (n = 42) 
Latent TB only (n = 26) 
Insuﬃcient reporng (n=28) 
Mean costs not shown (n = 10) 
Duplicate primary data (n=11) 
Data from before 1990 (n=7) 
Children only (n=8) 
Not peer reviewed (n=5) 
Papers included  
(n = 90) 
TB costs only 
(n = 71) 
TB and MDR-TB costs 
(n = 10) 
MDR-TB costs only 
(n = 9) 
Fig. 1 Literature review flow
chart. MDR multidrug-resistant,
TB tuberculosis
942 Y. V. Laurence et al.
Table 1 Summary of treatment cost papers included in review
References Year Country Interventions evaluated in study Provider
costs
included
Direct
patient
costs
included
Productivity
losses
included
HICs (n = 25)
Burman et al. [38]a 1997 USA DOT vs. self-administered therapy X X
Palmer et al. [92] 1998 USA Universal vs. partial DOT X
Migliori et al. [76] 1998 Russia New vs. old treatment strategies X
Migliori et al. [78] 1999 Italy DOT vs. DOT with staff incentives X X
Marchand et al. [93] 1999 Canada Hospitalised treatment of elderly X
Weis et al. [33] 1999 USA DOT vs. traditional therapy X
Wurtz and White [88] 1999 USA Traditional therapy X
White and Moore-Gillon [23]a 2000 UK Hospitalised treatment X
MacIntyre et al. [94] 2001 Australia Inpatient vs. outpatient therapy X
Jacobs et al. [30] 2002 Russia DOTS vs. traditional treatment X X X
Rajbhandary et al. [28]b 2004 USA MDR-TB X X
Atun et al. [40] 2006 Russia TB control system X
Kang et al. [31]b 2006 South Korea MDR-TB X X X
Bocchino et al. [48] 2006 Italy Integrated in- and outpatient X
Burns and Harrison [39] 2007 New Zealand DOT in non-resident population X
Kik et al. [29] 2009 Netherlands Household costs of immigrants X X
Miller et al. [52] 2010 USA Total TB costs in a Texas county X X
Montes-Santiago et al. [65] 2010 Spain Hospitalisation only X
Tu et al. [95] 2011 Taiwan Comparison of diagnostic methods X
Eralp et al. [51] 2012 UK Screening, diagnosis and treatment X
Diel et al. [24]a 2012 Germany Hospital and outpatient X X
Floyd et al. [55]b 2012 Estonia, Russia Traditional vs. WHO approach X
Miller et al. [41]a 2013 Latvia DOTS and MDR-TB X
Marks et al. [56]b 2014 USA Hospitalisation X X
Diel et al. [87]b 2014 Germany WHO guidelines X X
UMICs (n = 29)
Masobe et al. [43] 1995 South Africa Isoniazid prophylactic therapy X
Wilkinson et al. [49] 1997 South Africa DOT vs. traditional treatment X X X
Sawert et al. [77] 1997 Thailand TB programme improvements X X
Dick and Henchie [26] 1998 South Africa TB programme in Cape Town X
Xu et al. [60]a 2000 China DOTS vs. traditional treatment X
Suarez et al. [62]b 2002 Peru MDR-TB 2nd line drug treatment X
Kamolratanakul et al. [61]a 2002 Thailand Comparison of delivery centres X
Moalosi et al. [45] 2003 Botswana Home-based vs. hospital DOT X X X
Ruiz et al. [96] 2003 Mexico National costs X
Costa et al. [81]a 2005 Brazil Treatment in Salvador state X X X
Sinanovic and Kumaranayake [97] 2006 South Africa Public–private partnership model X
Peralta Perez et al. [53] 2006 Cuba DOTS X
Jackson et al. [98] 2006 China Household costs X X
Liu et al. [99] 2007 China Household costs X
Elamin et al. [72] 2008 Malaysia Costs in Penang state X X X
Cusmano et al. [44] 2009 Argentina DOTS X X X
Guzman-Montes et al. [100] 2009 Mexico Household costs X X
Fairall et al. [42] 2010 South Africa Educational outreach services X X
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Table 1 continued
References Year Country Interventions evaluated in study Provider
costs
included
Direct
patient
costs
included
Productivity
losses
included
Rouzier et al. [86]a 2010 Ecuador Household costs X X
Steffen et al. [14] 2010 Brazil DOTS vs. non-DOTS X X X
Prado et al. [80] 2011 Brazil Guardians vs. heath workers X X X
Samandari et al. [101]a 2011 Botswana DOTS for DS-TB and MDR-TB X
Nieto et al. [102] 2012 Colombia Increased guardian supervision X X
Schnippel et al. [57]b 2013 South Africa Hospitalised management X
Pooran et al. [25]b 2013 South Africa MDR-TB X
Zou et al. [103] 2013 China DOTS incentives vs. no incentive X X X
Pan et al. [63] 2013 China DOTS X X
Wei et al. [104] 2014 China DOTS X
Foster et al. [105] 2015 South Africa DOTS X X
LMICs (n = 17)
Rajeswari et al. [106] 1999 India Household costs X X
Khan et al. [47] 2002 Pakistan Health worker vs. family X X X
Vassall et al. [46] 2002 Egypt, Syria DOTS vs. previous strategies X X X
Nganda et al. [66] 2003 Kenya Increased community involvement X X X
Peabody et al. [107] 2005 Philippines Economic burden of TB X X
Tupasi et al. [58]b 2006 Philippines DOTS-Plus MDR-TB X X
Floyd et al. [34] 2006 India Public-private mix DOTS X X X
El-Sony et al. [54] 2006 Sudan Comparison of HIV? and HIV- X
Aspler et al. [108] 2008 Zambia Household costs X X
Muniyandi et al. [83] 2008 India DOTS vs. non-DOTS X X
Pantoja et al. [32] 2009 India Public-private mix DOTS X X X
John et al. [82] 2009 India DOTS X X
Vassall et al. [35] 2009 Ukraine DOTS implementation X X
Mahendradhata et al. [79] 2010 Indonesia Private practitioner referral X X X
Mauch et al. [109] 2011 Kenya Household costs X X
Umar et al. [110] 2012 Nigeria Household costs X
Mauch [68] 2013 Dom. Republicc,
Ghana, Vietnam
Household costs X X
LICs (n = 19)
Saunderson [50] 1995 Uganda Hospital vs. ambulatory care X X X
Maponga et al. [89] 1996 Zimbabwe TB/HIV co-epidemic X
Gibson et al. [111] 1998 Sierra Leone Household costs X
Wyss et al. [67] 2001 Tanzania Household costs X X
Islam et al. [73] 2002 Bangladesh CHW vs. no CHW X X X
Floyd et al. [36] 2003 Malawi Increased community involvement X X X
Okello et al. [37] 2003 Uganda Increased community involvement X X X
Wandwalo et al. [85] 2005 Tanzania Community vs. health facility X X X
Jacquet et al. [64] 2006 Haiti DOTS expansion X X X
Karki et al. [112] 2007 Nepal Public–private partnership X X X
Mirzoev et al. [113] 2008 Nepal Community vs. family observation X X X
Aye et al. [69] 2010 Tajikistan Household costs X X
Datiko et al. [84] 2010 Ethiopia Health extension workers X X X
Vassall et al. [74] 2010 Ethiopia Collaborative TB-HIV X X
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Table 1 continued
References Year Country Interventions evaluated in study Provider
costs
included
Direct
patient
costs
included
Productivity
losses
included
Pichenda et al. [59]a 2012 Cambodia Early diagnosis and non-hospital X X X
Laokri et al. [114] 2013 Burkina Faso Household costs X
Yitayal et al. [71] 2014 Ethiopia DOTS X X
Laokri et al. [115] 2014 Benin DOTS X
Gospodarevskaya
et al. [75]
2014 Bangladesh, Tanzania DOT female community
worker; DOT family
X X
X indicates the category of cost (Provider, Direct patient, or Productivity losses)
CHW community health worker, DOT directly observed treatment, DOTS directly observed treatment—short course, DS-TB drug-susceptible
tuberculosis, HIC high-income country, LIC low-income country, LMIC lower-middle income country, MDR-TB multidrug-resistant tubercu-
losis, UMIC upper-middle income country, WHO World Health Organization
a Both DS-TB and MDR-TB costs
b MDR-TB costs only
c Dominican Republic is an upper-middle income country
Table 2 Quality assessment: percent of papersa,b
Mean
number of
patients in
study
samplec
Ingredient
approach
used for
provider
costs
Resource use
and unit
costs clearly
described
Year of
cost
data
reported
Main cost
categories
clearly
separated
Descriptive
statistics
presented
Patient
interviews
Methods for
valuing
productivity
loss clearly
explained
Sources for
productivity
losses
assumptions
justified
Papers with provider costs only (n = 28)
HIC
(n = 15)
307 73 60 80 73 20 NA NA NA
UMIC
(n = 11)
384 100 73 91 82 9 NA NA NA
LMIC
(n = 1)
1797 0 0 0 100 0 NA NA NA
LIC
(n = 1)
300 100 0 100 0 0 NA NA NA
Papers with patient costs included (n = 62)
HIC
(n = 10)
475 89 82 82 82 45 18 82 64
UMIC
(n = 18)
305 91 78 61 83 22 94 61 56
LMIC
(n = 16)
345 63 94 88 81 50 94 69 50
LIC
(n = 18)
154 73 78 78 89 33 100 56 44
All papers 324 81 76 77 80 30 83 65 52
HIC high-income countries, LIC low-income country, LMIC lower-middle income country, NA not applicable, UMIC upper-middle income
countries
a These results are shown for each study in the Electronic Supplementary Material (Online Resources 2 and 3)
b Data are presented as % unless otherwise indicated
c Among the studies with patient-level data
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3.3.2 Provider Costs
The ingredient approach, which entails determining re-
source quantities and unit costs separately, is generally
viewed as the most robust and transparent method for
provider cost estimation [27]. This approach was trans-
parently used in 54 of the 67 studies that included provider
costs. While the method may also have been partly used in
the remaining 13 studies, techniques were not clearly de-
scribed, and resource quantities and unit costs were not
separately presented in these papers.
3.3.3 Patient-Incurred Costs
Patient interviews were conducted in 52 of the 62 studies
that included a patient perspective. The mean sample size
was 298 (SD 527) patient interviews, ranging from 13
patients in a US study to 3510 in the German cost-of-illness
study [24, 28]. Patient interviews were more common in
LICs and middle-income countries than in HICs. While ten
studies from HICs included patient-incurred costs, inter-
views were only conducted in two of these, a study from
Holland assessing costs among immigrant TB patients and
an economic evaluation of the Russian TB treatment
scheme and short-course chemotherapy [29, 30]. In the
other eight studies, productivity losses (and transport costs
in a study from South Korea [31]) were the only type of
patient costs included and these were estimated without
data from interviews.
Methods used for estimating productivity losses varied
in six different ways in the 51 papers that included these:
(1) patients were interviewed about their loss of income
(n = 15); (2) patients were interviewed about productive
time lost and on their income before falling ill; productivity
losses were then calculated by multiplying mean income
across the patient sample with reported time loss (n = 12);
(3) patients were interviewed about productive time lost,
which was multiplied by an official wage rate (n = 11); (4)
assumptions were made about the length of time patients
were not able to work, which was valued using an official
wage rate (n = 7); (5) a value was placed on death based
on average lifetime income or GNI per capita, which was
multiplied by estimated life-years lost (n = 4); and (6)
methods were not clear (n = 2). Across the 51 studies, only
Table 3 Mean drug-sensitive and multidrug-resistant tuberculosis provider treatment costs according to country income groupa
Income group Hospitalisation Outpatient visits Drugs Diagnostic and
monitoring tests
Otherb Totalc SDd
DS-TB
HIC (n = 19) 11,283 (8) 1471 (5) 1392 (6) 961 (7) 3413 (5) 14,659 (19) 13,594
UMIC (n = 19) 380 (5) 218 (10) 107 (14) 69 (11) 386 (9) 840 (19) 1105
LMIC (n = 10) 215 (4) 75 (6) 39 (6) 48 (8) 25 (5) 273 (10) 212
LIC (n = 11) 128 (2) 61 (5) 49 (8) 19 (3) 50 (8) 258 (11) 352
All income groups (papers = 58e) 4909 (19) 396 (26) 329 (32) 453 (26) 744 (27) 6667 (59) 10,105
Proportion, % 73.6 5.9 4.6 4.1 11.7 99.9
MDR-TB
HIC (n = 10) 53,078 (10) 18,720 (7) 19,887 (8) 1201 (6) 1841 (3) 83,365 (10) 64,825
UMIC (n = 7) 6056 (2) 622 (3) 2052 (6) 350 (5) 823 (5) 5284 (7) 3420
LMIC (n = 1) 207 (1) 218 (1) 2930 (1) 397 (1) 52,567 (1) 6313 (1) NA
LIC (n = 1) NI NI NI NI NI 1218 (1) NA
All income groups (papers = 18f) 41,776 (13) 12,102 (11) 11,623 (15) 779 (12) 1356 (9) 46219 (19) 61,027
Proportion, % 61.8 17.9 17.2 1.2 2.0 100.1
Data are presented as US$, year 2014 values (number) unless otherwise indicated
DS drug susceptible, HIC high-income country, LIC low-income country, LMIC lower-middle income country, MDR multidrug-resistant, NA not
applicable, NI cost not itemised, TB tuberculosis, UMIC upper-middle income country
a These are shown for each study in the Electronic Supplementary Material (Online Resources 4–7)
b Other provider costs include start-up costs, treatment supervision, staff salary and training, advocacy, adverse effects, contact tracing, supplies
and transportation; or in some papers, where costs were not disaggregated, the total treatment costs to the provider, including supervision,
training, supplies and drugs
c Total = sum of categories because some papers did not itemise costs and only reported total costs
d Vassall et al. [46] (2002) presented two LMIC studies (Egypt and Syria) in one paper
e Floyd et al. [55] (2012) presented two HIC studies (Estonia and Russia) in one paper
f Standard deviation for total mean provider treatment costs
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65 % clearly explained the methods used for productivity
losses, and 52 % justified the sources used for these
estimates.
3.4 Mean Costs Per Patient
Mean provider and patient-incurred costs per patient are
summarised in Tables 3 and 4 according to country income
groups. These data are presented for each study in the ESM
(Online Resources 4–7).
3.4.1 Drug-Susceptible (DS) Tuberculosis (TB) Provider
Costs
DS-TB provider costs were positively correlated with GNI
per capita (r = 0.73, p\ 0.001). A scatterplot illustrates
the relationship (Fig. 2). Mean DS-TB treatment costs per
patient were 57 times higher in HICs [US$14,659 (SD
13,594)] than in LICs [US$258 (SD 352)]. A high degree
of variability was observed in income group cost values,
with the SD being almost as large as the mean provider
costs in HICs and larger for LICs.
3.4.1.1 Hospitalisation and Outpatient Care Across all
59 studies, hospitalisation accounted for 74 % of all DS-
TB provider costs (Table 3). Hospitalisation accounted for
63 % in HICs (US$11,283), 51 % in LMICs (US$215) and
LICs (US$128), but only 12 % in UMICs (US$380).
However, within the income groups, the proportion of
hospitalisation costs varied widely between studies, with
2 % for an unreported number of hospital days in a public-
private sector implementation scenario in India to 81 % in
a study on DOT in Texas, USA, with 23 hospital days [32,
33]. Among LMICs, India consistently had the lowest costs
for hospitalisation and the other cost categories [32, 34]. In
LMIC costs, Ukraine had the highest hospitalisation and
outpatient costs, at approximately twice the average in-
come group costs [35]. Only two of the 11 LIC studies
Table 4 Mean drug-sensitive and multidrug-resistant tuberculosis direct patient costs and productivity losses according to country income
groupa
Income group Clinic visits and
clinical tests
user fees
Drugs Transport Otherb Total direct
costsc
SDd Productivity
losses
SDe
DS-TB
HIC (n = 6) 107 (1) NI 260 (1) 379 (1) 373 (2) 106 2801 (6) 2018
UMIC (n = 19) 221 (9) 62 (4) 120 (13) 491 (12) 603 (18) 868 600 (12) 847
LMIC (n = 17) 55 (9) 21 (7) 9 (4) 47 (10) 84 (17) 90 238 (11) 320
LIC (n = 19) 49 (13) 38 (5) 45 (10) 96 (16) 155 (19) 164 248 (14) 266
All income groups (papers = 53f, g, h) 101 (32) 36 (16) 82 (28) 212 (39) 432 (36) 544 700 (43) 1229
Proportion, % 23.3 8.5 19.1 49.1 100.0
MDR-TB
HIC (n = 5) CNI CNI 21 (1) CNI 21 (1) NA 49,204 (5) 51,216
UMIC (n = 2) 12 (2) NI 178 (2) 470 (2) 660 (2) 394 3532 (2) 4578
LMIC (n = 1) 909 (1) NI NI 707 (1) 1616 (1) NA CNI NA
LIC (n = 1) 103 (1) NI 18 (1) 285 (1) 406 (1) NA 1256 (1) NA
All income groups (papers = 9) 259 (4) NI 99 (4) 483 (4) 672 (5) 621 28,260 (8) 45,605
Proportion, % 30.8 0.0 11.7 57.4 99.9
Data are presented as US$, year 2014 values (number) unless otherwise indicated
CNI cost not included, DS drug susceptible, HIC high-income country, LIC low-income country, LMIC lower-middle income country, MDR
multidrug-resistant, NA not applicable, NI cost not itemised, SD standard deviation, TB tuberculosis, UMIC upper-middle income country
a These are shown for each paper in the Electronic Supplementary Material (Online Resources 4–7)
b Other patient costs typically include direct medical costs (non-TB drugs, hospitalisation) and direct non-medical costs (food, drink, vitamins,
traditional medicine, and accommodation), or in some papers, where costs were not disaggregated, the total costs during pre-diagnosis, diagnosis,
intensive treatment and continuation treatment phases
c Total = sum of categories because some papers did not itemise costs and only reported total costs
d Mauch et al. [68] (2013) presented one UMIC study (Dominican Republic) and two LMIC studies (Ghana and Vietnam) in one paper
e Vassall et al. [46] (2002) presented two LMIC studies (Egypt and Syria) in one paper
f Gospodarevskya et al. [75] (2014) presented two LIC studies (Bangladesh and Tanzania) in one paper
g SD for total mean patient costs
h SD for mean productivity losses
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reported hospitalisation costs, with US$75 (60 %) in
Malawi [36], and US$181 (50 %) in Uganda [37].
Mean outpatient treatment costs were 12 times less than
hospitalisation costs and accounted for only 6 % of total
costs. However, the importance of outpatient costs varied
substantially among country income groups. In HICs, only
five of 19 studies reported any outpatient costs [24, 38–41].
Of the ten UMIC studies that reported these costs, Ar-
gentina and South Africa had the lowest values of around
US$20 per patient [42–44] and Botswana the highest at
US$658 per patient [45]. Egypt was an outlier among the
LMICs, reporting outpatient costs of US$187 [46], which
was 15–25 times more than in Pakistan (US$11) and India
(US$6) [32, 47]. In LICs, five studies reported outpatient
costs, with a mean of US$61.
3.4.1.2 Drugs Costs of DS-TB drugs were, on average,
5 % of total costs, but varied widely between settings, from
a mean of US$49 across LICs to US$1392 in HICs. Within
the HICs, drug costs were US$311 in a US study [38],
US$654 in another US study [33], and as much as
US$4055 for an unstated combination of DS-TB and
MDR-TB drugs in Italy [48]. Within this group of coun-
tries, it is difficult to discern whether drug costs have de-
creased or increased over time because only six of the 19
studies presented disaggregated drug costs. In upper mid-
dle-income South Africa, drug costs appear to have de-
creased from US$46 in 1994 [49] to US$3 in 2003 [42]. In
LMICs and LICs, drug costs were lowest in India at ap-
proximately US$15 between 2002 and 2005 and highest in
Uganda at US$166 in 1992 [32, 34, 50]. Without these
outliers, mean drug costs in LMICs and LICs were US$51
and US$33, respectively, with data from between 1992 and
2007.
3.4.1.3 Diagnostics and Monitoring Tests Unlike the
costs of drugs and hospitalisation, mean costs per patient
for diagnostics and monitoring tests were relatively similar
across income groups. In the UK, costs of TB tests in a
population of healthcare workers were US$157 [51]. In
three US studies on urban DOT programmes by Miller
et al. [52], Burman et al. [38] and Weis et al. [33], costs per
patient were reported as US$124, US$635 and US$1505,
respectively. In the Miller et al. [52] study, only one acid-
fast bacilli (AFB) smear and culture was included, while
the other studies typically included at least two chest
X-rays, four sputum cultures and one tuberculin skin test
(TST). Burman et al. [38] additionally included five serum
bilirubin tests and five aspartate aminotransferase tests.
Interferon-Gamma Release Assay was used instead of
sputum culture in the UK study by Eralp et al. [51].
Although this review excluded latent TB, some studies
presented aggregated costs for diagnosis of latent TB to-
gether with tests for diagnosis and monitoring of active TB,
in which case the cost of the latent TB tests could not be
excluded.
Mean diagnostics and monitoring costs in UMICs were
US$69, with Cuba being the only outlier at US$289 in
2002 [53]. A Sudanese study that compared the costs of
managing HIV-positive and HIV-negative TB patients re-
ported the largest monitoring costs within this income
group at US$135 per patient [54].
3.4.2 Multidrug-Resistant-TB (MDR-TB) Provider Costs
Mean provider costs for MDR-TB treatment were
US$83,365 (SD 64,835) for the ten included studies and far
less for the seven UMICs at US$5284 (SD 3420). A large
variation in costs was observed for both groups; measures
of spread were not available for the LMIC and LIC groups
as there was only one study included in each of these
categories.
3.4.2.1 Hospitalisation and Outpatient Care MDR-TB
hospitalisation represented the highest proportion of pro-
vider costs in HICs, contributing to 64 % (Table 3). Even
though patients were hospitalised for an average of
192 days in Estonia, hospitalisation represented only 50 %
of total costs at US$8007 [55]. In the USA Burman et al.
[38] reported hospitalisation costs four times higher than
those reported by Rajbhandary et al. [28] because the
length of stay decreased from an average of 90 days in
1994 to 28 days in 2000 (US$181,909 vs. 41,612) [28, 38].
The mean length of MDR-TB hospitalisation in the USA in
2010, as reported by Marks et al. [56], remained 28 days,
but the cost, US$87,619, more than doubled the 2000 value
calculated by Rajbhandary et al. [28].
Fig. 2 Mean tuberculosis provider treatment costs per patient (US$,
year 2014 values) according to GNI per capita ($US, year 2013
values)
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In Russia, hospitalisation and outpatient care accounted
for 37 and 3 %, respectively, if treatment is delivered ac-
cording to WHO guidelines [55]. This Russian study re-
ported an average of 321 days in hospital, costing
US$6493, which was the second lowest value in the HIC
group. In South Korea, hospitalisation costs were the least
per patient (US$3521), but the length of stay was only
8 days, by far the shortest stay for any HIC or UMIC [31].
In South Africa, Schnippel et al. [57] reported a mean
hospitalisation period of 105 days, contrasting greatly with
Pooran et al. [25], who estimated costs according to pre-
vailing guidelines, which recommended complete outpa-
tient care for smear-negative MDR-TB patients [25, 57].
Pooran et al. [25] estimated that surgery, which we pre-
sented as a hospital cost, amounted to US$97 (2 %) per
patient, while outpatient visits totalled US$712 (17 %).
Schnippel et al. [57] reported no outpatient costs, but
hospitalisation accounted for 95 % of total MDR-TB costs
(US$12,666). Both treatment scenarios are present in South
Africa, but only 10 % of MDR-TB patients are thought to
require hospitalisation [25].
Only the Philippines were represented in the LMIC
group. In a DOT short-course plus pilot programme, hos-
pitalisation for 7 days amounted to 3 % and outpatient
visits to 4 % of total costs [58]. In the LIC group, no dis-
aggregated data were included for the one country repre-
sented, Cambodia, but the total MDR-TB cost was the
lowest value of any country at US$1218 [59].
3.4.2.2 Drugs In Estonia, 18 months of first- and second-
line drugs amounted to half of the hospitalisation costs
(192 hospital days) [55] (ESM Annex 5). The 2004 US
study by Rajbhandary et al. [28] did not separately report
costs of drugs, tests and personnel, but the 1997 US study
by Burman et al. [38] calculated MDR-TB drug costs as
amounting to approximately US$12,000 per patient (6 %)
[28, 38].
3.4.2.3 Diagnostic and Monitoring Tests Mean costs per
MDR-TB patient for diagnostics and monitoring tests were
US$779 (1 %) across the 12 studies reporting these data.
This accounted for less than 1 % of total treatment costs in
both the USA and the UK [23, 38]. In the South Korea
study, diagnostics and monitoring test amounted to 24 % of
total costs [31]. The costs reported in the UK were for drug
monitoring only, while Estonia, Germany, South Korea and
the USA (Burman et al. [38]) each included at least one
drug susceptibility test, 13 sputum culture tests and a
combination of audiograms (USA), sputum smear tests
(Estonia), X-rays, liver function and blood count tests.
The mean costs of diagnostics and monitoring tests were
US$350 in UMICs, ranging from US$82 in China to
US$1013 in South Africa [25, 60]. With the exception of
the South African study by Schnippel et al. [57], all studies
reported at least eight sputum smear tests. Costs of sputum
culture tests were included in all studies, with for instance
three tests per patient in 24 months in Thailand and 18 tests
per patient in 18 months in Peru [61, 62]. Costs of at least
four chest X-rays per patient were included in all UMIC
studies, except in South Africa where only one chest X-ray
was included and all patients were hospitalised during the
intensive phase of treatment [57]. Drug-susceptibility tests
were reported in Thailand and in the two studies from
South Africa [25, 57, 61]. In the only LMIC, the Philip-
pines, costs of 34 smear tests, 27 culture tests, two drug-
susceptibility tests and three X-rays were estimated at
US$397 per patient, equivalent to 6 % of total costs [58].
3.4.3 DS-TB Patient Costs
Across all 61 studies, in 57 papers, mean direct costs in-
curred by patients was US$432 (SD 544), ranging from
US$4 in Egypt to US$3525 in China (Table 4) [46, 63].
Approximately half of patient costs, the highest proportion,
was recorded in the ‘other’ category, which mainly con-
sisted of non-TB drugs and food while hospitalised, or
aggregated direct (medical and/or non-medical) patient
costs. User fees comprised 23 %, drugs 9 %, and trans-
portation 19 % of total costs. In contrast to provider costs,
there was no clear relationship between patient-incurred
costs and GNI per capita. UMIC studies reported the
highest mean patient costs (US$603), followed by two HIC
studies (US$373), LICs (US$155), and LMICs (US$84).
3.4.3.1 User Fees The user fees category comprised
costs incurred by patients for medical consultations or
examinations when attending clinics or other health fa-
cilities during treatment, or for diagnostic or monitoring
tests. Mean user fees payments were similar in high-in-
come Netherlands and upper-middle income Botswana at
around US$105. In the Netherlands, user fees accounted for
22 % of patient payments, but only for 11 % in Botswana
[29, 45].
Patients in upper-middle income Mexico and low-in-
come Haiti paid the highest user fees of US$344 and
US$299, respectively [64, 65]. The greatest proportion of
total direct costs spent on user fees were in India (80 %),
Kenya (69 %), South Africa (68 %) and Tanzania (66 %)
[34, 42, 66, 67]. In general, user fees appeared to constitute
the greatest proportion of patient costs in LMICs and
smallest in UMICs.
3.4.3.2 Drugs No out-of-pocket payments were paid for
drugs in HICs. Patients in Vietnam paid the least for drugs
(US$1), followed by the patients in the Dominican
Republic (US$5) [68]. Studies in Tajikistan and China
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reported the highest payments of US$126 and US$118,
respectively [69, 70]. In most LMICs, drug expenses were
around US$20, ranging between US$1 and US$63. Only
five studies reported payments for drugs in LICs, ranging
from US$4 in Ethiopia to US$126 in Tajikistan [69, 71].
3.4.3.3 Transportation The only HIC study that reported
transportation costs was in Russia, with US$260 [30].
Transportation costs in UMICs accounted for 1 % of direct
costs in the Dominican Republic and as much as 85 % in
Malaysia [68, 72]. In LMICs, patients paid an average of
US$9, accounting for between 2 and 28 % of total direct
costs. Ten of the 19 LIC studies reported transportation
costs, accounting for 80 % of direct costs in Bangladesh
and between 22 and 44 % in Ethiopia, Tajikistan and
Tanzania [67, 69, 71, 73–75].
3.4.3.4 Productivity Losses Time lost due to seeking
treatment and being ill with DS-TB was reported as
81 days in the Netherlands, 60 days in Thailand, 30 days in
Italy, 25 days in the USA, 14 days in Malaysia, and 50 %
disabled for 2 months in Haiti [29, 64, 72, 76, 77].
DS-TB productivity losses increased with increasing GNI
per capita, but amounts varied widely within country income
groups (SD 1229) with a mean loss of US$700 per patient for
43 studies. In HICs, values varied from US$450 in Russia to
US$6246 in Italy [30, 78]. In UMICs, the range was between
US$46 in Argentina and US$3048 in China [44, 63]. In
LMICs, an Indonesian study reported productivity losses of
US$12 per patient compared with US$996 in Vietnam [68,
79]. In LICs, costs were US$11 in Bangladesh versus
US$775 in Tajikistan [69, 73]. Studies from similar coun-
tries also showed quite different productivity loss estimates,
such as US$11 and US$332 in Brazil [80, 81], US$52 and
US$636 in India [82, 83], US$9 and US$200 in Ethiopia [71,
84], and US$18 and US$825 in Tanzania [67, 85].
3.4.4 MDR-TB Patient Costs
Mean direct costs incurred by MDR-TB patients were
US$672 (SD 621) across five studies (Table 4). The ‘other’
category constituted 57 % of total costs, which included
food, non-TB medication, follow-up tests and ventilation
improvements to family homes. No patient costs were re-
ported for MDR-TB drugs in any studies.
3.4.4.1 User Fees Similar to DS-TB user fees, MDR-TB
user fees incurred by patients were for medical consulta-
tions or examinations at health facilities or to obtain di-
agnostic or monitoring tests. The mean MDR-TB user fees
were US$259, which were almost three times higher than
for DS-TB. The Philippines reported the highest user fees
at US$909, accounting for 56 % of all direct MDR-TB
patient costs [58]. The user fees in low-income Cambodia
(US$103) were around eight times more than in UMICs
(US$4–20) [59]. No user fees were reported in HICs.
3.4.4.2 Transportation Mean transport costs incurred
from receiving DS-TB treatment were US$99 across the
four studies. The highest costs were reported in the two
UMICs, Brazil and Ecuador, at US$90 and US$266, re-
spectively [81, 86]. Studies from high-income South Korea
and low-income Cambodia each reported around US$20
per patient [31, 59].
3.4.4.3 Productivity Losses Productivity loss amounted
to US$28,260 per patient across the eight studies that in-
cluded these values. As with DS-TB, productivity losses
increased with income group, ranging from US$295 in
Brazil to US$136,802 in the USA and an overall SD of
US$45,605 [56, 81]. Only three studies, two from the USA
and one from Germany, clearly stated productive time lost
for MDR-TB, which was 6, 24 and 8 months, respectively
[38, 56, 87].
4 Discussion
Costs of TB treatment vary substantially globally, with
LICs adopting comparatively low-cost ambulatory methods
of treatment delivery and benefitting from lower drug
regimen prices than HICs. Provider costs are strongly
correlated with GNI per capita. The cost of treating DS-TB
from the provider perspective ranged from US$45 in
Zimbabwe to US$57,559 in one of the US studies [88, 89].
Provider costs of MDR-TB treatment are substantially
higher than those for DS-TB and varied from US$1218 in
Cambodia to US$204,876 in the USA [38, 59]. It should be
noted that many MDR-TB patients are primarily infected
with transmitted MDR-TB strains and do not acquire the
disease through misuse of their first-line regimen, so on the
individual level these are not always alternative treatments.
However, at a population level, the origins of MDR-TB lie
in the misuse of TB drugs, and the improved delivery of
first-line treatment can potentially reduce the level of
comparatively high MDR-TB treatment costs [90, 91].
We also observed substantial cost variation within
country income level groups. In the case of DS-TB, very
low comparative costs were observed in LICs and LMICs
using community-based models of care. While this sug-
gests that devolvement of TB treatment at the community
level may be efficient, the cost of community provision of
TB treatment depends strongly on whether community
workers are paid, and the valuation of their time. In the
case of MDR-TB treatment, the variation in costs within
country income level groups was also substantial. Lower
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cost treatment within groups was observed where primarily
ambulatory models of care are adopted, with hospitalisa-
tion being a major driver of total cost. Across DS-TB
treatment, there is a clear reduction in costs over time due
to the extent of hospitalisation decreasing as countries
moved towards ambulatory DOTS, although in countries
such as Germany, Spain, the USA and Latvia high hospi-
talisation costs were still reported between 2010 and 2013
[24, 41, 52, 65] (DS-TB patients were hospitalised for an
average of 115 and 72 days in Latvia and the USA, re-
spectively). Care should therefore be taken when using
costs from this review to estimate current costs for any one
setting to ensure that the cost applied reflects the current
mix of hospitalisation and ambulatory treatment. In par-
ticular, while the majority of MDR-TB treatment is cur-
rently provided in hospital, several countries are now
piloting ambulatory models of care, so these costs may fall
in coming years.
The costs of DS-TB drugs were reported in 34 studies.
When compared with DS-TB treatment, drug costs remain
a substantial component of MDR-TB treatment, and are
particularly high in countries using individualised MDR-
TB regimens and/or with high levels of extensively drug-
resistant (XDR) TB, or not accessing concessionary prices.
In the Philippines, MDR-TB drugs accounted for 46 % of
total provider costs in 2006 [58].
While there has been substantial research on direct costs
incurred by TB patients in low- and middle-income coun-
tries, these were only included in two HIC studies, possibly
highlighting a lesser interest in the poverty impact of TB in
countries with higher income levels and more compre-
hensive social protection and health insurance systems.
Nevertheless some patient costs were found. Kik et al. [29]
reported that immigrant DS-TB patients in Holland paid,
on average, US$486 to receive treatment [29]. In contrast,
in poorer countries, substantial attention has been paid to
patient-incurred costs. Although TB treatment is provided
free in many settings, it incurs a high economic burden,
either through out-of-pocket/direct payments (in some
settings ‘under-the-counter’ payments), but also through
substantial productivity loss. DS-TB direct patient costs
were, on average, US$603 in UMICs, US$84 in LMICs and
US$155 in LICs. The high values in LICs were noted by
many studies to be catastrophic, and are primarily driven
by costs captured in the ‘other’ category, which included
out-of-pocket payments made by patients and their social
networks for non-TB drugs, food and specialised diets,
traditional healers, and accommodation, among other costs.
The respective direct patient costs for MDR-TB patients
were US$660, US$1616 and US$406. There was substan-
tially less evidence on the patient cost of MDR-TB. The
few studies found highlight the potential of MDR-TB to
have a substantially higher catastrophic impact than DS-
TB. More research is required in this area, particularly to
better understand how these costs are incurred over time,
and how patient cost is affected by different levels of
hospitalisation.
Well defined estimates of productivity losses were in-
cluded in 81 % of DS-TB papers and 75 % of MDR-TB
papers. As a proportion of DS-TB patient costs, produc-
tivity losses comprised 96 % in HICs, 68 % in UMICs,
98 % in LMICs and 74 % in LICs. The methods used to
estimate productivity loss vary widely; nevertheless, it can
be seen that this is an important component of the eco-
nomic impact. Therefore, by excluding this cost, the ma-
jority of reported TB patient costs are substantially
underestimating the impact of TB on patients. The differ-
ence in methodological approaches taken also makes it
challenging to draw general conclusions about the key
drivers of patient-incurred costs, and for analysts to use this
review to extrapolate patient costs across settings or over
time. It is therefore recommended that, although the costs
presented in this review provide some guidance, the mea-
surement of setting-specific costs that are comprehensive
may still be required in economic analyses of TB control
interventions for some time to come.
We captured 90 papers in all income groups. The review
of economic evaluations in TB control published by Ver-
dier et al. [4] in 2011 included 118 papers from HICs only.
This large volume was due to the inclusion of mathematical
modelling papers and multiple papers using the same pri-
mary data. For MDR-TB, 16 countries were included in our
review, compared with only four countries captured by
Fitzpatrick and Floyd in 2012 [7]. Quality assessment is
crucial for systematic reviews, but only three of the pre-
vious reviews completed this [2, 4, 5]. Using the CHEERS
and TBCTA guidelines, we identified several key
methodological issues that suggest further standardisation
is required in order to further develop a set of costs that can
be used globally. First, even when the ingredient approach
to costing was used, cost items were insufficiently
separated in several studies, hindering our ability to ob-
serve cost drivers and analyse trends such as drug costs
over time. The lack of reporting of disaggregated costs was
also an issue for patient-incurred costs. Second, methods
for calculating productivity losses were not clearly ex-
plained in more than one-third of the studies that included
these costs, and disparate approaches were used between
studies, which led to widely different estimates within the
same country. The lack of standard methods for identifi-
cation, measurement and valuation of productivity losses
have frequently been acknowledged in the wider literature
on the measurement of costs, and minimum standardised
approaches are urgently required to enable comparisons
across settings, particularly in light of the increased global
attention on social protection [13]. Third, even though cost
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data were collected from a relatively large number of pa-
tients, insufficient statistical analyses were undertaken in
most studies. In addition to mean values, descriptive
statistics, such as SD, minimum and maximum values must
be presented and any outliers in the patient sample should
be highlighted.
5 Conclusion
In summary, literature on the costs of DS-TB treatment to
both providers and patients is extensive. However, evidence
is still scarce on the costs of treating MDR-TB, and how
these costs may vary by mode of delivery and setting.
MDR-TB treatment is rapidly evolving; a recent global
guideline change recommends Xpert MTB/RIF diagnos-
tics, which is more sensitive and also detects rifampicin
resistance, therefore identifying more cases. In addition,
recent global investment in further testing of existing MDR-
TB drugs as well as development of new drugs has been
substantial. More data are urgently required to estimate the
budgetary impact of these changes and to support economic
evaluations of new MDR-TB control approaches.
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